Clinical-stage biotech developing inhaled molgramostim for autoimmune pulmonary alveolar proteinosis, a rare lung disease.
Clinical-stage biotech developing inhaled molgramostim for autoimmune pulmonary alveolar proteinosis, a rare lung disease.
Has no product on sale, so it earns no sales; development is funded by money raised from investors. Its only late-stage drug is aimed at a rare disease, so the company's value depends on regulators approving that one drug and then on selling to a small patient group.
Moat: narrow (IP / patents, regulatory licence). First potential approved therapy for a rare disease with no current approved treatment.
Headquarters: Langhorne, Pennsylvania, US · Employees: 70
Size Savara (SVRA) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.04B, the 2206th largest of 3,085 United States companies the cockpit tracks. Shares closed at $4.72 on 18 Nov 2026.
Performance Over six months the shares fell 7.1%, against -10.6% for the median peer and -2.2% for the United States market (cap-weighted) — 9th highest of 21 in its peer set.
Short interest Short interest is 15.7% of the free float (30 Oct 2026).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$301,000 | -$245,000 | -$275,000 | -$175,000 | -$167,000 |
| EBITDA | -$157M | -$123M | -$103M | -$59.8M | -$38.7M |
| Net income | -$153M | -$119M | -$95.9M | -$54.7M | -$38.1M |
| Free cash flow | -$131M | -$101M | -$89.1M | -$51.4M | -$34.6M |
| Capital expenditure | $631,000 | $22,000 | $25,000 | $296,000 | $9,000 |
| Total debt | $30.4M | $29.9M | $26.8M | $26.7M | $26.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Savara SVRA | $1.04B | -7% | n/a | n/a | n/a | n/a |
| Insmed INSM | $26.3B | +3% | +240% | -42% | 17.0× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SVRA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.8% | -5.9% | 7th highest of 21 |
| 6-month return | -7.1% | -10.6% | 9th highest of 21 |
| Distance from 52-week high | -32.6% | -31.7% | 9th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Savara SVRA | United States | $1.04B | -7% | n/a | n/a | n/a | n/a | n/a |
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.04B | +33% | +5% | 24% | 3.2× | -5.6% | +12.7% |
| Sunflower Pharmaceutical 002737.SZ | China | $1.04B | -11% | +31% | -7% | 1.7× | -6.5% | -7.7% |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.05B | -18% | -7% | 3% | 1.5× | 2.5% | +6.5% |
| Blue Jet Healthcare BLUEJET.NS | India | $1.05B | +19% | -7% | 28% | 8.1× | 40.8% | +13.8% |
| Towa Pharmaceutical 4553.T | Japan | $1.03B | -10% | +7% | 9% | 1.2× | -0.3% | +12.1% |
| Everest Medicines 1952.HK | Hong Kong | $1.05B | -20% | +193% | -5% | 3.0× | n/a | n/a |
| Chengdu Easton Biopharmaceuticals 688513.SS | China | $1.03B | -33% | -2% | 13% | 4.2× | 4.4% | +7.7% |
| Jiangxi Fushine Pharmaceutical 300497.SZ | China | $1.02B | -23% | +103% | 24% | 4.0× | 7.5% | -4.5% |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.02B | +1% | +27% | 4% | 2.3× | 4.3% | +3.5% |
| Renhe Pharmacy 000650.SZ | China | $1.01B | -12% | -7% | 14% | 0.9× | -10.7% | -7.0% |
| SAWAI 4887.T | Japan | $1.01B | -18% | +2% | 9% | 1.3× | n/a | n/a |
| Omeros OMER | United States | $1.08B | +24% | n/a | -56% | 17.3× | n/a | n/a |
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.00B | -49% | +32% | 14% | 19.3× | n/a | n/a |
| North China Pharmaceutical 600812.SS | China | $1.08B | -12% | -21% | 5% | 2.4× | 1.0% | -4.2% |
| Aurisco Pharmaceutical 605116.SS | China | $1.00B | -23% | +3% | 25% | 4.2× | -2.0% | +18.7% |
| Shanghai InnoStar Bio-tech 688710.SS | China | $1,000M | +17% | +24% | 6% | 5.2× | 12.7% | +19.4% |
| MedinCell MEDCL.PA | France | $1.09B | +4% | -23% | -131% | 49.6× | n/a | n/a |
| PYC Therapeutics PYC.AX | Australia | $1.09B | +29% | n/a | n/a | n/a | n/a | n/a |
| Jiangsu Kanion Pharmaceutical 600557.SS | China | $989M | -9% | +8% | 7% | 1.4× | 2.3% | +1.8% |
| Aarti Pharmalabs AARTIPHARM.NS | India | $984M | +44% | +13% | 18% | 4.7× | n/a | n/a |